FOR-OD-26-003
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed)
Summary
Small Business Technology Transfer (STTR) Program — NIH Multi-Institute Initiative
The NIH is preparing to launch a Small Business Technology Transfer (STTR) program inviting U.S. small business concerns to develop biomedical technologies and translational research solutions across multiple institutes and centers. The program targets collaborative research combining small business technological expertise with academic or research institution capabilities to advance the NIH's research and development missions. Eligible research spans neuroscience (NINDS), immunology, cardiovascular biology, genetics, aging, substance use disorders, environmental health, neurobiology, mental health, nursing research, health disparities, clinical translation, and cancer biology. The initiative seeks to accelerate technology development and commercialization pathways from bench to market, with emphasis on Phase I feasibility studies and Phase II scaled development.
Critical note: This opportunity is not currently accepting applications. Publication depends on STTR program reauthorization and extension; applicants should monitor for formal solicitation before investing significant effort.
- Who can apply: United States small business concerns only; non-U.S. entities and non-small businesses are ineligible. Collaborative partnerships with research institutions are encouraged.
- Funding & project length: Not stated (Phase I and Phase II mechanisms typically differ; consult NIH STTR guidelines).
- Award mechanism: STTR Phase I, Phase II, Fast-Track, and Phase IIB grants (R41/R42 activity codes).
- Key dates: Not stated; formal NOFO publication pending reauthorization.
- Best fit for: Small biomedical device, diagnostic, therapeutic, or software companies with research collaborators seeking to translate early-stage discoveries into commercial products across neuroscience, immunology, oncology, and related fields.
Insights (5)
STTR reauthorization uncertainty creates fundamental application timeline risk
The opportunity explicitly states applications are "not being solicited at this time" and publication is "contingent upon reauthorization and extension." This means the program may never be funded, or funding could be delayed significantly. Researchers should not treat this as an imminent deadline and should verify reauthorization status before investing substantial effort in proposal development.
Small business concern status is a hard gate; verify SBC classification early
Only United States small business concerns are eligible; this excludes academic institutions, large companies, and non-U.S. entities entirely. If your organization is not independently classified as an SBC by SBA standards, you cannot apply regardless of research merit. Confirm SBC status with your business development office before committing to this mechanism.
Research institution partnerships are encouraged but require careful structuring
The NOFO explicitly encourages "collaborative investigations combining expertise" and notes that small businesses should "begin considering applying" with research partners. In STTR, the small business must be the lead applicant with a research institution as a subawardee (typically contributing 30-40% of effort). Ensure your research partner institution is willing to play a supporting role rather than lead.
NINDS and 20+ other NICs create broad but competitive research scope
The opportunity spans 21 NIH institutes including NINDS, NHLBI, NCI, and others across biomedical research fields (F27, F13, F24, F30, F28). This breadth is an opportunity if your technology addresses a priority area, but also signals high competition. Identify which specific IC's mission most closely aligns with your innovation to strengthen positioning.
STTR Phase I/II structure favors technology-ready small businesses over early-stage ventures
R41 (Phase I) and R42 (Phase II) mechanisms are designed for small businesses with demonstrable research capabilities and technological expertise ready for commercialization. This is not a mechanism for pre-seed ventures or proof-of-concept stage ideas; you should have preliminary data or a working prototype to be competitive.
Key Facts
Deadline
—
Posted
Wed, June 18, 2025
Keywords
Research Areas
Gotchas (2)
Eligibility explicitly limited to United States small business concerns (SBCs); non-U.S. entities or non-small businesses are ineligible
98%
Source Text
“invite eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I, Phase II, Fast-Track, and Phase IIB grant applications”
STTR program funding is contingent on reauthorization and extension; applications are not currently being solicited, creating uncertainty about whether this opportunity will actually be available.
95%
Source Text
“Publication of this solicitation is contingent upon reauthorization and extension of the STTR program. Applications are not being solicited at this time.”